Gleiss Lutz Advises Ackermans & van Haaren on Investment in DISCOPharmaceuticals

Gleiss Lutz advised the Belgian investment and holding company Ackermans & van Haaren NV as co‑lead investor in a seed financing round for DISCO Pharmaceuticals GmbH. The transaction comprises a EUR 36 million seed financing round in the biotech company DISCO Pharmaceuticals. Through its subsidiary AvH Growth Capital, Ackermans & van Haaren will, subject to certain conditions, invest up to EUR 9 million in multiple tranches and will initially hold a 12.4% stake. DISCO Pharmaceuticals, founded in May 2022 as a spin‑off from ETH Zurich and based in Cologne (Germany) and Schlieren (Switzerland), applies proteomics technology to map the surfaceomes of cancer cells. The new funds will enable the advancement of multiple antibody‑drug conjugate (ADC) candidates for small‑cell lung cancer and colorectal cancer into IND‑enabling studies. Ackermans & van Haaren is a diversified group that provides growth financing to sustainable companies across various sectors. Listed on Euronext Brussels and included in the BEL20 index, the group reported 2024 revenues of EUR 7.6 billion, a net profit of EUR 460 million and employed over 24,000 people. Gleiss Lutz represented Ackermans & van Haaren with a team composed by: Dr. Martin Viciano Gofferje (partner, M&A, Berlin) and Dr. Christoph Prawit Meissner (M&A, Berlin) leading the mandate; Malte Benfeldt (M&A, Berlin); Konrad Jankiewicz (M&A, Berlin); Dr. Enno Burk (partner, Healthcare & Life Sciences); Christoph Schoppe (Healthcare & Life Sciences); Sophie Römer (Healthcare & Life Sciences); Dr. Rut Steinhaser (partner, Employment); Angela Tschech (Employment); Jan Felix Hinrichs (IP/Tech, Berlin); Michael P. Clever (Real Estate, Frankfurt); and Aylin Hoffs (counsel, Foreign Trade Law, Düsseldorf). Gleiss Lutz regularly advises investors and companies on financing rounds in innovative industries such as biotech, artificial intelligence and deep tech and has recently advised TRUMPF SE on the entry of investors into its subsidiary Q.ANT.

Gleiss Lutz Advises Ackermans & van Haaren on Investment in DISCOPharmaceuticals

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads